Anabolic-Androgenic Steroids: Harm Reduction Through Education
The UK has a steroid problem. Pretending it does not exist helps nobody. Here is what you need to know to reduce the risks.
The Elephant in the Gym
Anabolic-androgenic steroid (AAS) use in the UK is not a fringe behaviour. Reliable figures are hard to obtain, but surveys and needle and syringe programme data suggest that use is widespread.
The demographic is not what most people imagine. AAS users are not exclusively elite athletes or competitive bodybuilders. They are office workers, tradesmen, students, and weekend gym-goers. Access through online sources has made pharmaceutical and underground-lab products available to anyone with a debit card.
Pretending this is not happening, or treating it purely as a criminal justice issue, does not reduce harm. The reality is that a large number of people in the UK are using powerful hormonal drugs, often with little or no medical oversight or routine monitoring.
Why Blood Monitoring Matters
AAS use without blood monitoring is driving blind. The drugs raise androgens to supraphysiological levels, and the effects on organ systems can be significant, often without symptoms until they are advanced.
The most dangerous aspect of AAS use is not the side effects you can see or feel. It is the ones you cannot. Cardiovascular risk rises during a cycle: Lipid Profile typically shows HDL cholesterol falling, sometimes sharply, while LDL increases, creating a more atherogenic environment. This lipid shift, sustained across multiple cycles, is thought to be one of several contributors to the higher heart attack and stroke risk reported in long-term users.
Liver Function (ALT, AST, GGT) can reveal hepatotoxicity, particularly with oral compounds like Oxandrolone, Methandrostenolone, and Stanozolol. Elevated liver enzymes can be an early warning sign of liver injury, although normal results do not rule out every liver problem.
Full Blood Count is critical because AAS stimulate erythropoiesis, driving up red blood cell production. Elevated Haemoglobin and Haematocrit increase blood viscosity, raising the risk of blood clots, stroke, and cardiac events. This can be a serious effect of AAS use, and it shows up on a routine blood test.
Blood testing does not make AAS use safe. Nothing does. But it can make some hidden risks visible and measurable, which is one part of harm reduction.
What Your Blood Reveals During and After a Cycle
A comprehensive blood panel taken during a cycle can reveal some of the physiological cost that the mirror does not show.
Testosterone (total and free) and LH/FSH indicate the degree of hypothalamic-pituitary-gonadal (HPG) axis suppression. During an AAS cycle, exogenous androgens signal the brain to shut down natural testosterone production. LH and FSH often fall to near zero, and natural production largely stops. Knowing how deep this suppression is can help when you discuss recovery with a doctor.
Oestradiol rises as excess testosterone is aromatised. Elevated oestrogen can contribute to gynaecomastia (breast tissue development), water retention, mood disturbance, and further disruption of the HPG axis. Monitoring means changes can be picked up and discussed with a doctor, rather than guessed at.
Kidney Function (creatinine, eGFR) is worth tracking because AAS can place additional strain on the kidneys, particularly alongside the elevated blood pressure that commonly accompanies use. High muscle mass and creatine supplements can raise creatinine without any kidney damage, so results need interpreting in context.
Prolactin may rise with some compounds, and raised prolactin can contribute to sexual dysfunction.
Post-cycle, repeat blood tests can show whether natural hormone production is recovering. Many users assume recovery is complete based on how they feel, but subjective perception is unreliable. If your hormone levels stay low after stopping, speak to your GP, as long-term hypogonadism may need medical treatment.
Pharmaceutical Grade Does Not Mean Safe
One of the most persistent myths in AAS communities is that pharmaceutical-grade products eliminate the health risks. They do not.
Genuine pharmaceutical-grade drugs are made to regulated standards for purity, dosing, and sterility. These are meaningful advantages over underground-lab products, which frequently contain incorrect doses, contamination, or substituted compounds. Products sold as pharmaceutical grade without a prescription can also be counterfeit. Genuine products reduce the additional risks of unknown substances, but they do not eliminate the risks of the substances themselves.
Testosterone, Nandrolone, Trenbolone, and Oxandrolone all carry risks to cardiovascular health, hormonal balance, and fertility, regardless of how pure the product is, and oral compounds such as Oxandrolone can also affect the liver. The physiological impact of supraphysiological androgen levels is inherent to the mechanism of action. You cannot dose your way around it.
Cardiac remodelling (left ventricular hypertrophy) has been documented in long-term AAS users. Adverse lipid changes are common. HPG axis suppression occurs with every compound. Fertility impairment, including azoospermia (zero sperm production), is common during use and can persist long after cessation in some individuals.
If you use AAS, regular blood testing is one way to monitor what these drugs are doing to your body. It does not make use safe, but it can make some of the risks visible and measurable, so you can discuss them with a doctor. Your GP can give confidential advice about steroid use and its effects on your health. Needle and syringe programmes, offered by many pharmacies and local drug services, provide free sterile injecting equipment and harm reduction advice to people who inject steroids.
If You Choose to Monitor
Our Performance panels include some of the markers discussed here: full blood count and kidney function in every tier, plus lipids and testosterone in Silver and Gold. No judgement, just data.